Render Target: STATIC
Render Timestamp: 2024-11-21T13:46:41.581Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-10-04 20:01:10.132
Product last modified at: 2024-07-10T07:01:36.665Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a
  1. Products /
  2. Primary Antibodies /
  3. BRD4 Antibody Sampler Kit

BRD4 Antibody Sampler Kit #82970

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    The BRD4 Antibody Sampler Kit provides an economical means of detecting various BRD4 isoforms. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Background

    Bromodomain-containing protein 4 (BRD4) is a member of the bromodomains and extra terminal (BET) family of proteins, which also includes BRD2, BRD3, and BRDT (1-3). BET family proteins contain two tandem bromodomains and an extra terminal (ET) domain, and bind acetyl lysine residues (3). BRD4 is a chromatin-binding protein with a preference for Lys14 on histone H3 as well as Lys5 and Lys12 on histone H4 (4). BRD4 chromatin binding occurs throughout the cell cycle, including condensed mitotic chromosomes, when the majority of genes are silenced (5). BRD4 association with chromatin during mitosis is thought to be an important part of the bookmarking mechanism to accelerate reactivation of the silenced genes upon exit from mitosis (2,6). BRD4 has been shown to facilitate transcription by recruiting the positive transcription elongation factor b (pTEFb) complex that phosphorylates Ser2 of the heptapeptide repeat of the carboxy-terminal domain of RNA polymerase II, promoting transcription elongation (3,7,8). In addition, BRD4 has been found to be part of the super elongation complex and the polymerase associated factor complex (PAFc) in MLL-fusion derived leukemia cell lines, demonstrating a role for BRD4 in the regulation of transcription elongation (9). Research studies have shown that BRD4 (and BET family proteins) may be promising therapeutic targets for various Myc-driven cancers, such as Burkitt’s lymphoma and certain acute myeloid leukemias (1,10,11). Investigators have found molecular inhibition of BET proteins to be effective in inducing apoptosis in various MLL-fusion driven leukemic cell lines by competing BRD3 and BRD4 from chromatin, leading to reduced expression of Bcl-2, Myc, and CDK6 (9). BET inhibition has also been shown to have antitumor activities against nuclear protein in testis (NUT) midline carcinoma cell lines and xenografts in mice where BRD4 is found to be a frequent translocation partner of the NUT protein (12). In addition, BRD4 regulates the expression of some inflammatory genes, and inhibition of BRD4 (and BET family proteins) chromatin binding causes reduced expression of a subset of inflammatory genes in macrophages, leading to protection against endotoxic shock and sepsis (13).

    The expression of BRD4 isoform C, also known as the short isoform (BRD4-S), is similar to the long isoform (BRD4-L). The balance of expression between the two isoforms has been shown to contribute to disease states, where BRD4-S has shown to be oncogenic in a few contexts (14-16). BRD4-S is the predominant isoform that binds to modified histones and has a stronger affinity than BRD4-L (17,18). BRD4-S also plays a role in DNA damage, where it recruits the condensin II complex to enhance DNA damage induced cell death (18).
    1. Belkina, A.C. and Denis, G.V. (2012) Nat Rev Cancer 12, 465-77.
    2. Voigt, P. and Reinberg, D. (2011) Genome Biol 12, 133.
    3. Wu, S.Y. and Chiang, C.M. (2007) J Biol Chem 282, 13141-5.
    4. Dey, A. et al. (2003) Proc Natl Acad Sci U S A 100, 8758-63.
    5. Dey, A. et al. (2009) Mol Biol Cell 20, 4899-909.
    6. Zhao, R. et al. (2011) Nat Cell Biol 13, 1295-304.
    7. Jang, M.K. et al. (2005) Mol Cell 19, 523-34.
    8. Yang, Z. et al. (2005) Mol Cell 19, 535-45.
    9. Dawson, M.A. et al. (2011) Nature 478, 529-33.
    10. Muller, S. et al. (2011) Expert Rev Mol Med 13, e29.
    11. Mertz, J.A. et al. (2011) Proc Natl Acad Sci U S A 108, 16669-74.
    12. Filippakopoulos, P. et al. (2010) Nature 468, 1067-73.
    13. Nicodeme, E. et al. (2010) Nature 468, 1119-23.
    14. Wu, S.Y. et al. (2020) Mol Cell 78, 1114-1132.e10.
    15. Crawford, N.P. et al. (2008) Proc Natl Acad Sci USA 105, 6380-5.
    16. Fernandez, P. et al. (2014) Cell Rep 9, 248-260.
    17. Wang, R. et al. (2012) J Biol Chem 287, 10738-52.
    18. Han, X. et al. (2020) Nat Struct Mol Biol 27, 333-341.

    Database Links

    UniProt ID: O60885-3 , O60885 , O60885-2


    Entrez-Gene Id: 23476


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.